Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna (NASDAQ:MRNA) on Monday, setting a price target of $164, which is approximately 16.30% above the present share price of $141.01.
R. Cann expects Moderna to post earnings per share (EPS) of -$0.59 for the fourth quarter of 2020.
The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Moderna, with an average price target of $123.21.
The analysts price targets range from a high of $200 to a low of $60.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $157.91 million and a net profit of -$235.12 million. The company's market cap is $43.2 billion.
According to TipRanks.com, Brookline Capital Markets analyst Leah R. Cann is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.6% and a 49.80% success rate.
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.